PB 75 of 2014
National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 6) – specification under subsection 84AAA(2)
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 23 September 2014
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________________
Amendment determination – Pharmaceutical Benefits – Early Supply
1 Name of Instrument
(1) This Instrument is the National Health (Pharmaceutical Benefits – Early Supply) Amendment Instrument 2014 (No. 6) – specification under subsection 84AAA(2).
(2) This Instrument may also be cited as PB 75 of 2014.
2 Commencement
This Instrument commences on 1 October 2014.
3 Amendment of PB 30 of 2009
Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) (PB 30 of 2009).
Schedule 1 Amendments
[1] Schedule 1, entry for Aclidinium
omit from the column headed “Form”:
containing aclidinium bromide 400 micrograms per dose, 60 doses
substitute:
322 micrograms (as bromide) per dose, 60 doses
[1] Schedule 1, entry for Alendronic Acid
omit:
Tablet 40 mg (as alendronate sodium)
Oral
30
5
[2] Schedule 1, entry for Oestradiol and oestradiol with dydrogesterone
insert as first entry in the columns in the order indicated:
Pack containing 14 tablets oestradiol 1 mg and 14 tablets oestradiol 1 mg with dydrogesterone 10 mg
Oral
1
5
[3] Schedule 1, after entry for Oestradiol and oestradiol with norethisterone in the form Pack containing 4 transdermal patches
780 micrograms oestradiol (as hemihydrate) and 4 transdermal patches 620 micrograms oestradiol (as hemihydrate) with 2.7 mg
norethisterone acetate
insert:
Oestradiol with dydrogesterone
Tablet 1 mg-5 mg
Oral
28
5
